Hoosier Cancer Research Network investigators presented a trials in progress poster featuring the HCRN study GU17-295 during the American Society of Clinical Oncology’s 2020 Genitourinary Cancers Symposium on Friday, Feb. 14, in San Francisco, Calif.

The poster, titled, “Phase II trial of atezolizumab plus chemotherapy after progression on single-agent PD-1 or PD-L1 inhibitor in cisplatin ineligible patients with advanced urothelial carcinoma HCRN GU17-295,” was presented during Trials in Progress Poster Session B: Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers. See abstract.

“This phase two study aims to investigate continuation of immunotherapy beyond progression and the addition of chemotherapy in patients with cisplatin-ineligible metastatic urothelial carcinoma,” said Nabil Adra, MD, MSc, sponsor-investigator of the study and a researcher at the Indiana University Melvin and Bren Simon Cancer Center. “If successful, we would like to investigate the mechanism of re-sensitizing tumors to immunotherapy with the addition of chemotherapy.”

The study authors, include:

• Nabil Adra – Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Ind.
• Ralph J. Hauke – Nebraska Cancer Specialists, Omaha, Neb.
• Hristos Z. Kaimakliotis – Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Ind.
• Shuchi Gulati – University of Cincinnati Medical Center, Cincinnati, Ohio
• Neda Hashemi – University of New Mexico, Albuquerque, N.M.
• Roberto Pili – Roswell Park Cancer Institute, Buffalo, N.Y.

“The Hoosier Cancer Research Network staff have been instrumental in the success of this current study and other clinical trials,” Dr. Adra said. “HCRN provides substantial benefit to investigators, from the time of idea generation, trial design, and submission for funding, to recruiting other cancer centers to open the study, trial activation, and data analysis.”

For more information about this research study, including full eligibility requirements, visit clinicaltrials.gov (study #NCT03737123).

About Hoosier Cancer Research Network:

Hoosier Cancer Research Network (formerly known as Hoosier Oncology Group) conducts innovative cancer research in collaboration with academic and community physicians and scientists across the United States. The organization provides comprehensive clinical trial management and support, from conception through publication. Created in 1984 as a program of the Walther Cancer Institute, Hoosier Cancer Research Network became an independent nonprofit clinical research organization in 2007. Since its founding, Hoosier Cancer Research Network has conducted more than 210 trials in a variety of cancer types and supportive care, resulting in more than 350 publications. More than 8,500 subjects have participated in Hoosier Cancer Research Network clinical trials.